Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HER3 and mutant EGFR meet MET.

× No keyword cloud information.

34 in total

Review 1. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.

Authors: Yu Sunakawa; Heinz-Josef Lenz
Journal: Curr Treat Options Oncol Date: 2015-04

Review 2. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

Authors: Woody Han; Hui-Wen Lo
Journal: Cancer Lett Date: 2012-01-17 Impact factor: 8.679

Review 3. Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.

Authors: Carlos L Arteaga
Journal: Curr Top Microbiol Immunol Date: 2010 Impact factor: 4.291

4. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion.

Authors: Rui Wang; Rajat Bhattacharya; Xiangcang Ye; Fan Fan; Delphine R Boulbes; Lee M Ellis
Journal: Mol Cancer Res Date: 2018-08-21 Impact factor: 5.852

5. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.

Authors: Wei-Chien Huang; Yun-Ju Chen; Long-Yuan Li; Ya-Ling Wei; Sheng-Chieh Hsu; Shing-Ling Tsai; Pei-Chun Chiu; Wei-Pang Huang; Ying-Nai Wang; Chung-Hsuan Chen; Wei-Chao Chang; Wen-Chang Chang; Andy Jer-En Chen; Chang-Hai Tsai; Mien-Chie Hung
Journal: J Biol Chem Date: 2011-04-12 Impact factor: 5.157

6. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.

Authors: Shoumin Zhu; Abbes Belkhiri; Wael El-Rifai
Journal: Gastroenterology Date: 2011-07-07 Impact factor: 22.682

7. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.

Authors: Lin Wang; Zhi-Xia Zhu; Wen-Ying Zhang; Wei-Min Zhang
Journal: Exp Ther Med Date: 2011-06-22 Impact factor: 2.447

8. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.

Authors: Tobias Ach; Katharina Zeitler; Stephan Schwarz-Furlan; Katharina Baader; Abbas Agaimy; Christian Rohrmeier; Johannes Zenk; Martin Gosau; Torsten E Reichert; Gero Brockhoff; Tobias Ettl
Journal: Virchows Arch Date: 2012-12-15 Impact factor: 4.064

Review 9. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

Authors: Kyle W Robinson; Alan B Sandler
Journal: Oncologist Date: 2013-01-23

Review 10. The ERBB3 receptor in cancer and cancer gene therapy.

Authors: G Sithanandam; L M Anderson
Journal: Cancer Gene Ther Date: 2008-04-11 Impact factor: 5.987